More drug studies and trials on the way! - CLL Support

CLL Support

23,339 members40,047 posts

More drug studies and trials on the way!

AussieNeil profile image
AussieNeilPartnerAdministrator
2 Replies

Good to see the search for improved CLL treatments continues:

1) A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

clinicaltrials.gov/ct2/show...

This is a study evaluating the efficacy, safety, and pharmacodynamics of GS-9973 in subjects with chronic lymphocytic leukemia (CLL), etc.

See also Dr Jeff Sharman's post about this trial at:

cll-nhl.com/2013/04/new-stu...

2) Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (includes CLL and SLL)

Purpose: To determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab

clinicaltrials.gov/show/NCT...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
2 Replies
HAIRBEAR_UK profile image
HAIRBEAR_UKFounder Admin

Thanks Neil, there does seem to be a lot going on. Dr Sharman's blog is really helping to translate the new work and approaches in an understandable way. The landscape is changing we are fortunate to have someone so able to convey thoughts and map this for us.

Your post reminds me of words spoken at recent group meetings by clinical researchers. It is going to become increasingly important to have a consultant with a special interest in CLL on your team able to navigate the growing number of clinical trials available at research hospitals.

Dave3579 profile image
Dave3579

I have never met Dr Sharman, but have the highest regard for him based on the amount of comitment he makes to building a bridge between the patient and the medical world he is a part of through his blogs. he goes into great detail on every aspect of CLL and to have someone who is highly placed in the treatment and design of treatments who reaches out and explain in a clear way to CLLers. I like his candid comments and also the fact he holds out hope to the frightened sufferer that good things are coming. His blog is a must read

Not what you're looking for?

You may also like...

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

Oncology live May 06, 2020 The time-limited triplet of umbralisib, ublituximab, and venetoclax...
Jm954 profile image
Administrator

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL

"This Phase Ib/IIa study is a multicenter open label trial of the combination of IPH2201 and...
AussieNeil profile image
Partner

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE)

The Lancet, Feb22nd 2021. Jeff P Sharman, Mato et al Patients with chronic lymphocytic leukaemia...
Jm954 profile image
Administrator

Moderation team

See all
AussieNeil profile image
AussieNeilAdministrator
Newdawn profile image
NewdawnAdministrator
CLLerinOz profile image
CLLerinOzAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.